---
title: "Fosun Pharma: The holding subsidiary's drug has been approved for clinical trials in late-stage solid tumors"
description: "Fosun Pharma's subsidiary HENLIUS recently received approval from the National Medical Products Administration to conduct clinical trials for the injection of HLX43 combined with HLX07 for the treatme"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/259482859.md"
published_at: "2025-09-30T08:51:30.000Z"
---

# Fosun Pharma: The holding subsidiary's drug has been approved for clinical trials in late-stage solid tumors

> Fosun Pharma's subsidiary HENLIUS recently received approval from the National Medical Products Administration to conduct clinical trials for the injection of HLX43 combined with HLX07 for the treatment of advanced/metastatic solid tumors, planning to carry out Phase Ib/II trials. HLX43 is a PD-L1 targeted antibody-drug conjugate, and HLX07 is an innovative biological drug targeting EGFR. The research and development investment is approximately 150,000 yuan, and there are currently no similar drugs approved for marketing globally, so investors should be aware of the research and development risks

Recently, Shanghai Fosun Pharmaceutical Holdings subsidiary HENLIUS received approval from the National Medical Products Administration to conduct clinical trials for the injection HLX43 in combination with HLX07 for the treatment of advanced/metastatic solid tumors, with plans to carry out Phase Ib/II trials domestically. HLX43 is a PD-L1 targeted antibody-drug conjugate, while HLX07 is an innovative biopharmaceutical targeting the EGFR. As of September 30, 2025, multiple clinical studies for HLX43 are being conducted in various locations worldwide, and several Phase II clinical studies related to HLX07 are underway domestically. As of August, the total R&D investment for this treatment plan has reached approximately 150,000 yuan, and there are currently no similar combination drugs approved for marketing globally. Since the drug is still in the clinical trial stage, there are risks associated with R&D, and investors are reminded to pay attention to investment risks

### Related Stocks

- [02696.HK - HENLIUS](https://longbridge.com/en/quote/02696.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 安德森斯｜10-K：2025 财年营收 110 亿美元不及预期 |  | [Link](https://longbridge.com/en/news/276269991.md) |
| 宏盟集团｜10-K：2025 财年营收 173 亿美元不及预期 |  | [Link](https://longbridge.com/en/news/276492573.md) |
| 科力斯｜10-K：2025 财年营收 6.69 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276490864.md) |
| 布鲁克代尔老年关怀公司｜10-K：2025 财年营收 30.54 亿美元 |  | [Link](https://longbridge.com/en/news/276380056.md) |
| IRhythm｜10-K：2025 财年营收 7.47 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276388892.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.